Capricor Therapeutics Inc... (CAPR)
Capricor Therapeutics Inc. (CAPR) Stock Price, Analysis & Data
| Bid | 3.04 |
| Market Cap | 244.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -114.59M |
| Beta | 0.53 |
| EPS (ttm) | -2.32 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.34 |
| P/B (ttm) | 0.87 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 13, 2026 |
| Ask | 5.05 |
| Volume | 924,895 |
| Avg. Volume (20D) | 2,852,629 |
| Open | 3.93 |
| Previous Close | 3.93 |
| Day's Range | 3.90 - 4.27 |
| 52-Week Range | 2.96 - 40.37 |
| Analyst | Hold |
| Price Target | 4.25 (0.71%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...
Financial Performance
In 2025, Capricor Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 22.27M. Earnings were -105.04M, an increase of 159.58%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for CAPR stock is "Hold". The 12-month stock price forecast is 4.25, which is upside of 0.71% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
